Affiliation:
1. Universidade Federal Fluminense, Brasil
Abstract
ABSTRACT The purpose of this case series is to report eight patients with giant prolactinomas emphasizing presentations and a treatment complication. The study group included six men and two women. The median age was 29 years (18–54 years); median serum prolactin level was 4,562 ng/ml (1,543–18,690 ng/ml); three patients (37.5%) had panhypopituitarism; median tumor diameter was 50 mm (41–60 mm). Five patients (62.5%) had visual field defects and three had improvement during treatment; six patients (75%) reached prolactin normalization, with a median time of 10.5 months (7–84 months) and median dose of 2.0 mg/week (1.0 to 3.0 mg/week). One patient presented as a true incidentaloma. One patient presented a cerebrospinal fluid leakage during medical treatment and refused surgery, however this resolved with conservative measures. This case series illustrate a rare subtype of macroprolactinomas, the importance of considering unusual presentations at the diagnosis, the effectiveness of pharmacological treatment and its possible complications.
Subject
Neurology,Clinical Neurology
Reference19 articles.
1. Management of prolactinomas;Molitch ME;J Clin Endocrinol Metab,1997
2. Giant prolactinomas: clinical management and long-term follow up;Shrivastava RK;J Neurosurg,2002
3. Giant prolactinomas in men: efficacy of cabergoline treatment;Corsello SM;Clin Endocrinol (Oxf),2003
4. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia;Colao A;Eur J Endocrinol,2003
5. Gender-related differences in prolactinomas: a clinicopathological study;Schaller B;Neuro Endocrinol Lett,2005
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Our experience in prolactinomas larger than 60 mm;Endocrinología, Diabetes y Nutrición;2021-01
2. Our experience in prolactinomas larger than 60 mm;Endocrinología, Diabetes y Nutrición (English ed.);2021-01
3. Cabergoline;Reactions Weekly;2016-09